Quest Diagnostics Inc. (DGX) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic path...
Quest Diagnostics Inc. (DGX) currently trades at a P/E ratio of 24.42 (historical range: 7.58–25.68, median: 19.80), placing it at the 97th percentile — expensive relative to its history, P/S ratio of 2.24 (range: 1.38–2.35, 97th percentile — expensive relative to its history), EV/EBITDA of 19.46 (range: 7.46–20.05, 97th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Quest Diagnostics Inc.'s P/E ratio has expanded by 52% over the observed period (from an average of 14.1 to 21.4).
Quest Diagnostics Inc. trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 24.42 | 19.80 | 97th | expensive relative to its history |
| P/S Ratio | 2.24 | 1.73 | 97th | expensive relative to its history |
| EV/EBITDA | 19.46 | 16.17 | 97th | expensive relative to its history |
| FCF Yield | 5.20% | 6.05% | 15th | expensive relative to its history |
Quest Diagnostics Inc. (DGX) Valuation & P/E History
Quest Diagnostics Inc. (DGX) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry currently trading at $235.00 with a market capitalization of $25.9 billion. This page provides historical valuation analysis for DGX based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 24.42 is above the historical median of 19.80, placing DGX at the 97th percentile of its valuation range. The P/S ratio of 2.24 compares to a median of 1.73.
DGX Valuation Metrics & Historical Range
The valuation table above shows Quest Diagnostics Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether DGX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests DGX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Quest Diagnostics Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is DGX Overvalued or Undervalued?
Quest Diagnostics Inc. trades well above its own historical valuation range across most metrics. The overall valuation percentile of 97 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive DGX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full DGX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.DGX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.